-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Pharmaceutical Stock Market] The biopharmaceutical sector of Hong Kong stocks continued to strengthen.
For example, WuXi Junuo rose more than 20%, WuXi AppTec rose nearly 7%, WuXi Biologics rose 5%, BeiGene rose more than 4%, and Junshi Bio rose.
nearly 4%
.
So what are the recent developments of these companies? WuXi Ju Nuo continued its recent rally, and WuXi Ju Nuo-B accelerated its gains in intraday trading today
.
It is reported that WuXi Junuo announced last Friday that the CAR-T therapy product "Ruijirenxai Injection" (JWCAR029) has been approved for marketing for adult patients with relapsed or refractory severe disease after second-line or above systemic therapy.
B-cell lymphoma
.
Ruijirensai is a CAR-T product approved for listing in China, and it is also a Category 1 CAR-T approved in China
.
It is reported that WuXi Junuo’s Ruiki Orenza injection is a drug that has simultaneously obtained major new drug development projects, priority review qualifications for new drug marketing applications (r/r LBCL), and breakthrough therapy drug designation (follicular lymphoma).
) and other three honors have been approved CAR-T products
.
WuXi AppTec has recently upgraded its ESG rating to AA in MSCI's newly released "Environmental, Social and Corporate Governance" (ESG) annual rating results.
Governance” and “Product Safety and Quality” performed well
.
The upgrade of the MSCI ESG rating fully demonstrates and demonstrates WuXi AppTec's firm belief in integrating environmental and social responsibility into the company's strategy and operations
.
WuXi AppTec provides multi-faceted and integrated new drug R&D and production services for the global biopharmaceutical industry, empowering partners to promote the process of new drug R&D and bring breakthrough treatment options to patients
.
As an enabler of the global health industry, WuXi AppTec attaches great importance to all aspects of ESG management, and continuously improves ESG-related aspects including corporate governance and behavior, product safety and quality, human resource development, environmental protection, and corporate social responsibility.
Work
.
WuXi Biologics recently indicated that the anti-PD-1 fully human innovative antibody drug Sepalizumab (GLS-010) jointly developed by Yuheng Pharmaceuticals and WuXi Biologics has been approved by the NMPA for marketing as a second-line treatment Patients with relapsed or refractory classical Hodgkin lymphoma (r/r cHL) above
.
In addition, according to the company's first half performance report, in the first half of this year, WuXi Biologics' realized revenue increased by 126.
7% year-on-year to RMB 4.
41 billion; gross profit increased by 191.
7% year-on-year to RMB 2.
3 billion, and gross profit margin increased by 1160 basis points to 52.
1%.
Double the growth and hit a new high
.
The good performance has also made WuXi Biologics a biopharmaceutical CDMO company, with a current market value of more than 500 billion Hong Kong dollars
.
BeiGene recently announced that Anjave (denosumab injection) has been approved by the National Medical Products Administration for its new indication marketing application in China for the prevention of bone metastases from solid tumors and bone-related events caused by multiple myeloma.
FDA approval as the RANKL inhibitor approved for this indication
.
In addition, BeiGene recently announced that its self-developed BTK inhibitor (zanubrutinib) has been approved by the United States (FDA) for the treatment of adult patients with Waldenström macroglobulinemia (WM)
.
This is the first product that BeiGene has approved to go overseas in the United States
.
Junshi Bio It is reported that Junshi Bio’s performance has improved significantly, and the two commercialized products have been very successful
.
The company has continuously increased investment in research and development, and has made breakthroughs.
While expanding new targets and new drugs horizontally, it has also vertically tapped more new indications on the same target to achieve value enhancement
.
In terms of internationalization, the company actively participates in international academic conferences, and utilizes a globally integrated R&D platform to achieve simultaneous IND application and clinical trials with the United States, and obtain more global rights.
.
Therefore, Junshi Bio, which insists on R&D innovation and global output, is expected to gain a larger product market in the future and enhance the overall value of the company
.
For example, WuXi Junuo rose more than 20%, WuXi AppTec rose nearly 7%, WuXi Biologics rose 5%, BeiGene rose more than 4%, and Junshi Bio rose.
nearly 4%
.
So what are the recent developments of these companies? WuXi Ju Nuo continued its recent rally, and WuXi Ju Nuo-B accelerated its gains in intraday trading today
.
It is reported that WuXi Junuo announced last Friday that the CAR-T therapy product "Ruijirenxai Injection" (JWCAR029) has been approved for marketing for adult patients with relapsed or refractory severe disease after second-line or above systemic therapy.
B-cell lymphoma
.
Ruijirensai is a CAR-T product approved for listing in China, and it is also a Category 1 CAR-T approved in China
.
It is reported that WuXi Junuo’s Ruiki Orenza injection is a drug that has simultaneously obtained major new drug development projects, priority review qualifications for new drug marketing applications (r/r LBCL), and breakthrough therapy drug designation (follicular lymphoma).
) and other three honors have been approved CAR-T products
.
WuXi AppTec has recently upgraded its ESG rating to AA in MSCI's newly released "Environmental, Social and Corporate Governance" (ESG) annual rating results.
Governance” and “Product Safety and Quality” performed well
.
The upgrade of the MSCI ESG rating fully demonstrates and demonstrates WuXi AppTec's firm belief in integrating environmental and social responsibility into the company's strategy and operations
.
WuXi AppTec provides multi-faceted and integrated new drug R&D and production services for the global biopharmaceutical industry, empowering partners to promote the process of new drug R&D and bring breakthrough treatment options to patients
.
As an enabler of the global health industry, WuXi AppTec attaches great importance to all aspects of ESG management, and continuously improves ESG-related aspects including corporate governance and behavior, product safety and quality, human resource development, environmental protection, and corporate social responsibility.
Work
.
WuXi Biologics recently indicated that the anti-PD-1 fully human innovative antibody drug Sepalizumab (GLS-010) jointly developed by Yuheng Pharmaceuticals and WuXi Biologics has been approved by the NMPA for marketing as a second-line treatment Patients with relapsed or refractory classical Hodgkin lymphoma (r/r cHL) above
.
In addition, according to the company's first half performance report, in the first half of this year, WuXi Biologics' realized revenue increased by 126.
7% year-on-year to RMB 4.
41 billion; gross profit increased by 191.
7% year-on-year to RMB 2.
3 billion, and gross profit margin increased by 1160 basis points to 52.
1%.
Double the growth and hit a new high
.
The good performance has also made WuXi Biologics a biopharmaceutical CDMO company, with a current market value of more than 500 billion Hong Kong dollars
.
BeiGene recently announced that Anjave (denosumab injection) has been approved by the National Medical Products Administration for its new indication marketing application in China for the prevention of bone metastases from solid tumors and bone-related events caused by multiple myeloma.
FDA approval as the RANKL inhibitor approved for this indication
.
In addition, BeiGene recently announced that its self-developed BTK inhibitor (zanubrutinib) has been approved by the United States (FDA) for the treatment of adult patients with Waldenström macroglobulinemia (WM)
.
This is the first product that BeiGene has approved to go overseas in the United States
.
Junshi Bio It is reported that Junshi Bio’s performance has improved significantly, and the two commercialized products have been very successful
.
The company has continuously increased investment in research and development, and has made breakthroughs.
While expanding new targets and new drugs horizontally, it has also vertically tapped more new indications on the same target to achieve value enhancement
.
In terms of internationalization, the company actively participates in international academic conferences, and utilizes a globally integrated R&D platform to achieve simultaneous IND application and clinical trials with the United States, and obtain more global rights.
.
Therefore, Junshi Bio, which insists on R&D innovation and global output, is expected to gain a larger product market in the future and enhance the overall value of the company
.
